Double-Filtration Plasmapheresis Versus Efgartigimod for Generalized Myasthenia Gravis: Severity-Stratified Benefits in a Prospective Observational Multicenter Study.

However, a clear trend toward superior, sustained benefit was observed in the DFPP group at T2 (ΔMG‐ADL: 4.00 ± 2.98 vs. 1.93 ± 3.47, p = 0.091; β = −2.07, p = 0.068), suggesting more sustained clinical benefits (Figure 2B ). 3.3.

also in 19,460 other papers

4.83 ± 0.61; p = 0.089) compared to the EFG group (Figure 2A ), though these between‐group differences did not reach statistical significance, potentially due to limited sample size. 3.2.1.2.

also in 111,027 other papers